|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits in other financial institutions and federal funds sold | ||||||||||||||||||||
| Cash and Cash Equivalents | ||||||||||||||||||||
| Investment securities available for sale, at fair value | ||||||||||||||||||||
| Restricted equity securities, at cost | ||||||||||||||||||||
| Real estate acquired through foreclosure | ||||||||||||||||||||
| Loans, net of deferred fees and costs | ||||||||||||||||||||
| Less: Allowance for credit losses | ||||||||||||||||||||
| Loans, net | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Accrued taxes receivable | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total Assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Noninterest-bearing deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total Deposits | ||||||||||||||||||||
| Short-term borrowings | ||||||||||||||||||||
| Defined pension liability | ||||||||||||||||||||
| Accrued taxes payable | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock, par value $1, authorized 15,000,000 shares, issued and outstanding 2,919,695 and 2,900,681 shares as of September 30, 2025 and December 31, 2024 respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Deferred compensation, restricted stock | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Stockholders' Equity | ||||||||||||||||||||
| Total Liabilities and Stockholders' Equity | ||||||||||||||||||||
Loading...
